mission
european
respiratori
societi
er
advanc
respiratori
medicin
stimul
coordin
action
member
order
achiev
highest
possibl
medic
paramed
social
standard
treatment
respiratori
diseas
europ
societi
congress
approxim
regist
particip
countri
scientif
clinic
session
congress
europ
largest
annual
scientif
gather
respiratori
medicin
respiratori
diseas
third
lead
caus
death
global
despit
rise
burden
lung
diseas
europ
recent
european
commiss
propos
next
research
programm
includ
lung
diseas
major
diseas
fund
categori
recent
er
report
estim
cost
lung
diseas
european
economi
billion
euro
per
year
larg
longterm
treatment
support
need
patient
chronic
lung
diseas
presid
er
professor
ronald
dahl
comment
rate
lung
diseas
rise
throughout
europ
live
lost
due
underfund
govern
refus
recognis
scale
problem
end
irish
republ
made
revolutionari
decis
implement
workplac
smoke
ban
doomsay
predict
hospit
industri
would
suffer
mani
bar
restaur
would
forc
close
custom
would
refus
visit
nonsmok
establish
howev
time
custom
accept
nonsmok
rule
go
establish
equal
import
irish
research
team
demonstr
year
smoke
ban
signific
reduct
indoor
particl
level
indic
air
insid
establish
much
cleaner
addit
lung
function
test
shown
lung
health
servic
industri
worker
nonsmok
exsmok
alreadi
improv
significantli
contrast
lung
function
smoker
continu
declin
thu
groundbreak
decis
irish
republ
led
improv
lung
health
citizen
norwegian
research
team
report
similar
result
month
smoke
ban
norway
servic
industri
worker
experienc
signific
decreas
respiratori
symptom
includ
morn
cough
daytim
cough
phlegm
cough
dyspnoea
dutch
research
team
report
result
followup
smoker
well
known
cigarett
smoke
import
risk
factor
develop
chronic
obstruct
pulmonari
diseas
copd
therefor
smoke
cessat
regard
best
prevent
measur
risk
odd
ratio
copd
develop
smoker
age
year
smoker
age
year
research
state
reduc
copd
incid
greatest
effort
put
smoke
cessat
programm
german
investig
report
result
larg
n
prospect
cohort
studi
studi
smoke
incid
asthma
adolesc
studi
popul
assess
follow
analysi
show
activ
smoker
increas
risk
develop
asthma
comparison
neversmok
author
conclud
activ
smoke
import
risk
factor
develop
asthma
adolesc
time
goe
increas
evid
show
stop
smoke
benefit
smoker
peopl
surround
area
peopl
remain
healthi
insur
scheme
fewer
bill
pay
reduct
cost
due
smoke
reduc
insur
premium
everyon
particip
congress
invit
govern
ban
smoke
public
area
includ
train
buse
bar
restaur
offic
factori
furthermor
govern
support
extens
programm
encourag
assist
cessat
smoke
govern
will
cooper
exist
programm
focu
smoke
cessat
asthma
chronic
inflammatori
disord
airway
characteris
recurr
episod
wheez
cough
breath
difficulti
current
estim
million
peopl
worldwid
asthma
number
forecast
rise
million
number
approxim
sever
asthma
inadequ
control
current
avail
therapi
sever
asthma
lead
increas
hospitalis
healthcar
utilis
death
clear
unmet
need
effect
safe
treatment
inadequ
control
sever
persist
asthma
believ
high
proport
asthma
case
trigger
allergen
scientist
discov
immunoglobulin
known
ige
later
scientist
determin
ige
play
central
role
asthma
sinc
ige
respons
initi
cascad
inflammatori
symptom
airway
constrict
short
breath
base
find
scientist
felt
ige
novel
target
develop
new
therapeut
agent
possibl
interven
earli
interrupt
allerg
cascad
target
ige
antibodi
omalizumab
firstinclass
recombin
humanis
monoclon
antibodi
bind
ige
antibodi
prevent
onset
allerg
inflammatori
cascad
addit
block
action
ige
omalizumab
shown
antiinflammatori
effect
benefit
asthma
patient
previou
studi
omalizumab
improv
control
sever
allerg
asthma
core
studi
extens
phase
er
congress
chung
et
al
report
result
longterm
control
openlabel
extens
clinic
trial
evalu
omalizumab
thu
patient
complet
second
extens
take
omalizumab
year
studi
show
omalizumab
effect
safe
persist
therapeut
effect
current
extens
increas
forc
expiratori
volum
second
fev
baselin
seen
extens
maintain
extens
indic
lung
function
improv
improv
accompani
sustain
decreas
inhal
corticosteroid
use
studi
demonstr
longterm
use
omalizumab
result
continu
excel
good
asthma
control
base
physician
assess
sever
persist
allerg
asthma
impact
patient
qualiti
life
physic
emot
social
aspect
patient
live
serious
impair
metaanalysi
six
control
clinic
trial
patient
sever
persist
allerg
asthma
show
omalizumab
significantli
improv
qualiti
life
dose
omalizumab
adjust
individu
base
bodyweight
baselin
total
ige
concentr
studi
drug
given
everi
week
subcutan
inject
professor
stephen
holgat
univers
southampton
uk
state
omalizumab
address
unmet
need
respiratori
diseas
omalizumab
launch
us
juli
sinc
prescrib
patient
juli
eu
committe
medicin
product
human
use
chmp
gave
posit
opinion
initi
market
authoris
omalizumab
specialist
lung
diseas
infecti
diseas
rememb
year
sever
acut
respiratori
syndrom
sar
epidem
unfortun
scientist
identifi
caus
agent
die
sar
time
sar
produc
panic
healthcar
system
overwhelm
hospit
sever
affect
intern
trade
depress
economi
mani
countri
today
sar
remain
major
health
threat
recent
case
singapor
taiwan
china
show
risk
continu
exist
thu
necessari
maintain
vigil
detect
new
case
control
sar
requir
earli
diagnosi
prompt
isol
suspect
case
singl
case
could
result
massiv
outbreak
diagnost
criteria
propos
world
health
organ
reli
microbiolog
test
presenc
specif
antisarscov
immunoglobulin
unfortun
presenc
antisarscov
immunoglobulin
usual
occur
day
symptom
onset
laboratori
requir
day
conduct
requir
analysi
scientist
hong
kong
develop
predict
rule
clinic
diagnosi
sar
predict
rule
help
clinician
initi
diagnosi
manag
potenti
sar
patient
tabl
author
state
predict
rule
appear
help
assess
suspect
patient
sar
bedsid
valid
sar
cohort
past
centuri
three
pandem
outbreak
influenza
kill
million
peopl
worldwid
sinc
know
avian
influenza
virus
differ
subtyp
transmit
human
directli
caus
diseas
death
professor
albert
osterhau
erasmu
medic
centr
netherland
warn
earli
warn
system
pandem
prepared
plan
must
develop
govern
readi
emerg
new
pandem
viru
question
happen
happen
studi
shown
mani
patient
asthma
copd
use
meter
dose
inhal
mdi
correctli
one
major
problem
method
deliveri
need
exactli
coordin
actuat
inhal
respimat
soft
improv
inhal
actuat
use
dosereleas
button
combin
slow
deep
inspir
addit
soft
last
approxim
time
longer
convent
mdi
mean
patient
use
respimat
soft
need
coordin
use
convent
mdi
kardo
et
al
undertook
observ
postmarket
cohort
studi
patient
mean
age
year
asthma
copd
receiv
addon
therapi
berodu
respimat
ipratropium
bromidefenoterol
via
soft
inhal
investig
evalu
efficaci
toler
handl
berodu
respimat
inhal
multicentr
studi
conduct
gener
practic
berodu
respimat
improv
dyspnoea
patient
asthma
patient
copd
reduc
nighttim
wake
asthma
copd
patient
respect
tabl
ii
advers
event
report
patient
n
end
studi
particip
continu
therapi
berodu
respimat
thu
studi
demonstr
asthma
copd
patient
found
new
soft
mist
inhal
effect
easi
use
inspir
intern
asthma
patient
insight
research
studi
global
evalu
asthma
patient
percept
one
object
assess
asthma
variabl
impact
manag
patient
attitud
treatment
inspir
first
studi
highlight
patient
readi
adjust
treatment
show
patient
may
abl
manag
asthma
recognis
act
warn
sign
occur
prior
asthma
worsen
one
object
inspir
assess
asthma
control
medic
use
organis
want
test
concept
warn
time
asthma
patient
studi
design
answer
follow
question
patient
receiv
warn
patient
recognis
warn
patient
know
receiv
warn
uk
previou
studi
shown
patient
say
asthma
control
howev
patient
also
say
use
rescu
therapi
daili
inspir
extens
telephon
interview
conduct
adult
moder
sever
asthma
european
union
countri
use
trade
name
product
identif
purpos
impli
endors
total
patient
use
longact
agonist
either
combin
separ
inhal
patient
use
inhal
corticosteroid
tabl
iii
overal
patient
least
one
asthma
exacerb
requir
medic
intervent
last
year
despit
regular
prescrib
mainten
treatment
asthma
patient
well
control
even
shock
even
wellcontrol
patient
averag
exacerb
per
year
mani
patient
confid
could
selfmanag
asthma
without
physician
visit
recognis
earli
warn
sign
exacerb
mean
period
earli
sign
peak
symptom
exacerb
day
furthermor
mean
time
recoveri
day
common
respons
sign
exacerb
increas
shortact
agonist
use
inhal
corticosteroid
use
increas
exacerb
reach
peak
patient
increas
inhal
corticosteroid
lesser
extent
shortact
agonist
professor
martyn
partridg
imperi
colleg
chare
cross
hospit
uk
discuss
fact
episod
worsen
asthma
symptom
patient
initi
increas
airway
open
reliev
therapi
increas
antiinflammatori
prevent
treatment
rel
late
exacerb
patient
adjust
treatment
exacerb
adjust
wrong
one
professor
partridg
emphasis
patient
increas
inhal
corticosteroid
suffici
increas
inhal
corticosteroid
rel
late
exacerb
stress
publish
evid
show
prompt
increas
type
treatment
like
prevent
deterior
asthma
control
need
unplan
healthcar
time
earli
warn
peak
worsen
offer
window
opportun
assist
asthma
patient
professor
partridg
stress
potenti
advanc
futur
treatment
strategi
would
probabl
result
use
current
effect
treatment
smarter
way
patient
must
taught
use
prevent
treatment
earlier
educ
key
sinc
patient
must
taught
method
given
tool
abl
effect
manag
asthma
healthcar
profess
respons
teach
patient
live
better
asthma
often
asthma
chronic
rather
acut
therefor
educ
must
continu
process
finland
norway
govern
involv
educ
asthma
patient
good
costbenefit
ratio
healthcar
system
effort
